BOARD 06 // ABOUT
About this Thymosin alpha-1 review board
What this site is, what it isn't, and how it reads the literature.
What this site is
Reviews / Thymosin Alpha-1 is an independent editorial project that publishes summaries of the peer-reviewed research literature on Thymosin alpha-1. The format is a chalked-out review board: every published trial gets opened, the dose and the endpoint and the result get chalked up, the citation gets pinned, and the editorial sticky-note margin carries the pull-quote that captures the finding.
The scope of the literature here is set: chronic hepatitis B and C (approved-indication trials), severe sepsis (the ETASS RCT and the pooled meta-analytic record), severe COVID-19 (the Wuhan and Italian observational cohorts plus 2023 meta-analyses), non-small-cell lung cancer mechanism and adjuvant work, the influenza-vaccine-adjuvant and post-transplant reconstitution trials, and the receptor-level mechanism work on TLR-9 and TLR-2.
What this site is not
Reviews / Thymosin Alpha-1 is not a clinic. It does not employ clinicians and it does not provide medical advice. It does not manufacture, sell, or distribute any product. It does not maintain a physical address, a phone number, or a patient roster. The work is editorial commentary on publicly available science.
The 'reviews' in the domain modifier is editorial framing — the position the publisher occupies relative to the literature (reviewing it, digesting it, chalking it out). It is not a claim about clinical services. The word should be read the way 'reviews' appears on a book-review or film-review site: an editorial stance on existing work.
How the literature is read here
The editorial method is conservative. Quantitative claims are cited to the source trial. Where a result is from a single RCT, the single-RCT status is stated. Where a result is pooled from a meta-analysis, the meta-analysis is cited and the heterogeneity is noted. Where evidence is observational rather than randomized — as with most of the COVID-19 record — the observational status is stated explicitly. Where a result reaches significance only with pooling (as with the sepsis 28-day mortality endpoint), that pattern is named rather than hidden behind 'studies suggest.'
Every PMID and DOI on the references page has been verified against the NCBI E-utilities esummary endpoint and the Crossref API. Where a citation could not be verified, it was omitted rather than padded. No claim is made about Thymosin alpha-1 that is not in the published literature this site cites.